Azithromycin versus Pivampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis: a Single-blind, Doubledummy, Multicentre Study
|
|
- Nickolas Wiggins
- 5 years ago
- Views:
Transcription
1 M Nomura, S Kida, J Yamashita The Journal et al. of International Medical Research Endovascular 2000; 28: Embolization of Unruptured Vertebral Dissection Azithromycin versus Pivampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis: a Single-blind, Doubledummy, Multicentre Study P SCHOUENBORG 1, N GERDES 2, HH RASMUSSEN 3, N WICKERS-NIELSEN 4 AND E MATHIASSEN 5 1 Department of Microbiology, Vejle Hospital, Vejle, Denmark; 2 Gothersgade 59, Frederica, Denmark; 3 Sæbyvej 17, Asaa, Denmark; 4 sterå 17, Aalborg, Denmark; 5 Rådhustorvet 4, Vejle, Denmark This single-blind, double-dummy, multicentre study compared oral azithromycin, administered as tablets, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in adults with acute exacerbations of chronic bronchitis (not needing parenteral antibiotic therapy, hospitalization or oxygen support). Clinical success (cure + improvement) rates were similar for both groups at the end of treatment (day 10; azithromycin, 124 of 133 [93%]; pivampicillin, 79 of 92 [86%]) and at follow-up (day 52; 98 of 126 [78%] versus 66 of 81 [81%]). The treatments produced similar levels of pathogen eradication at the end of treatment (49 of 54 [91%] versus 32 of 37 [86%]). Azithromycin-treated patients had significantly reduced chest discomfort at the end of treatment, and a trend towards improved lung function. The two groups were similar with respect to improvements in other clinical symptoms and patient well-being, and to the incidences of adverse events and treatment discontinuations. This oral azithromycin regime is an effective treatment for acute exacerbations of chronic bronchitis, similar in efficacy to the longer pivampicillin regime and may offer superior patient compliance. KEY WORDS: AZITHROMYCIN; PIVAMPICILLIN; ANTIBACTERIAL DRUGS; EXACERBATIONS OF CHRONIC BRONCHITIS; CHRONIC BRONCHITIS; PATIENT COMPLIANCE 101
2 INTRODUCTION The incidence of chronic obstructive pulmonary disease (COPD) in developed countries has increased sharply in recent decades. This disease is now the fifth leading cause of mortality and, with acute lower respiratory tract infections, the leading burden of disease among member states of the World Health Organization. 1 Chronic bronchitis is an important element of COPD and occurs frequently in both male and female patients of all ages. The clinical course of chronic bronchitis includes periodic exacerbations, which may be of infective (e.g. bacterial, viral) or noninfective (e.g. chemical agent) origin. Patients typically experience a median of three acute exacerbations per year, 2,3 up to 50% of which are bacterial in origin. 4,5 The most frequently reported causative organisms in acute bacterial exacerbations of chronic bronchitis (AECB) include Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, 6,7 which account for 85 95% of cases. 6 Other pathogens include haemolytic streptococci, Staphylococcus aureus and Gram-negative enteric bacilli. 7 Recent years have witnessed an increased awareness of the involvement of the atypical pathogens, Mycoplasma pneumoniae, Legionella species and Chlamydia pneumoniae, in AECB 6 and, to a greater extent, in community-acquired pneumonia. 8,9 A meta-analysis of randomized trials published up to 1994 indicated that there are significant advantages to be gained from the use of antimicrobial therapy in patients with AECB. 10 Patients classified as having AECB of Anthonisen Type 1 severity (defined as increases in dyspnoea, sputum volume and sputum purulence) were shown to benefit from treatment. 11 A 7 10-day course of broad-spectrum antibiotic therapy is normally recommended for AECB. 11 Conventional treatment options include trimethoprim/sulfamethoxazole and aminopenicillins (ampicillin, amoxycillin or amoxycillin/clavulanic acid) or erythromycin (in patients hypersensitive to penicillins). 7 Alternative treatments include various oral cephalosporins (such as cefuroxime axetil and cefprozil) and newer macrolides (azithromycin and clarithromycin), 7 which, unlike β-lactam antibiotics, are effective against atypical pathogens. Pivampicillin, an ampicillin ester, is better absorbed than ampicillin 12 and attains higher serum levels at comparable doses. 13 Clinical studies have demonstrated that the clinical efficacy of pivampicillin, administered twice or three times daily, is comparable with that of oral ofloxacin in treating purulent AECB, 14 and superior to that of amoxycillin in treating acute bronchitis. 15,16 Multiple daily doses 17 and longer (> 7 days) duration of treatment 18 are risk factors for poor patient compliance with medication, however, so the need remains for antibiotic agents that afford effective therapy with once-daily dosing and a short duration of treatment. The azalide azithromycin is structurally related to erythromycin. 19,20 The in vitro antimicrobial spectrum of azithromycin is superior to that of erythromycin and includes S. pneumoniae, H. influenzae and M. catarrhalis, as well as the atypical respiratory pathogens. 21 In addition, the unique pharmacokinetic profile of azithromycin, which includes phagocytemediated delivery to sites of infection, 22 leads to high respiratory tissue concentrations. 23,24 As a result, the intracellular levels of azithromycin exceed its minimum inhibitory concentrations against respiratory pathogens for up to 8 days, 25 enabling effective, short-duration therapy with once-daily dosing. 20 Clinical 102
3 studies have shown that a 3-day course of once-daily oral azithromycin is as effective clinically as other more frequently administered antibacterial agents across a range of indications, including respiratory tract infections. 20 In addition, azithromycin has an excellent tolerability/safety profile in adults and children. 26 A study was therefore conducted to compare oral azithromycin, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in the treatment of patients with AECB. The study drugs were evaluated for clinical and microbiological efficacy, frequency of relapse within 6 weeks of initiation of therapy, and safety and tolerability. PATIENTS AND METHODS STUDY DESIGN This randomized, single-blind, doubledummy, comparative study was performed in 47 Danish general practices. Written informed consent was obtained from all patients entering the study. Eligible patients comprised ambulatory men or women, 18 years old (with no upper age limit), with chronic bronchitis (defined as daily coughing and expectoration for more than 3 months within a 1-year period, and for 2 consecutive years without any other proven pulmonary disease) 27 and with an acute exacerbation (indicated by two or more of the following: increase in dyspnoea, increase in coughing and expectoration, body temperature > 38.5 C). Before initiation, the study was approved by the Danish National Board of Health and the Scientific Ethical Committee of Funen and Vejle. Criteria for exclusion from study entry included: suspected pneumonia; need for parenteral antibiotic therapy; need for hospitalization and/or oxygen support; terminal illness or other conditions precluding completion of the study or clinical evaluation; known hypersensitivity to macrolides or penicillins; pregnancy or lactation (women of child-bearing potential were required to use adequate contraception); treatment with another antimicrobial agent within 2 weeks (or with any investigational drug within 4 weeks) of study entry; concomitant treatment with carbamazepine, cyclosporine, digoxin or ergotamine; clinically significant hepatic or renal diseases (liver function tests more than twice the upper limit of normal, and serum creatinine level > 200 µmol/l); and any gastrointestinal disturbance that might affect study drug absorption. Eligible patients who entered the study at baseline (day 0) were randomized, using Geigy s random numbers, to receive one of two treatments: azithromycin 500 mg active tablets, once daily for 3 days, plus pivampicillin placebo tablets, twice daily for 10 days; or pivampicillin 700 mg active tablets, twice daily for 10 days, plus azithromycin placebo tablets, once daily for 3 days. Treatment was followed by a period of 42 days during which no antibiotic treatment was allowed. The study drugs were supplied to the investigators in study-specific medicine dispenser boxes, each labelled in accordance with Danish Health Authority Regulations for clinical drug supplies. A difference in the colour of pivampicillin active (white) and placebo (yellow white) tablets meant that treatment was blinded only with respect to the patients. Patients were assessed at baseline, at the end of treatment (day 10) and at follow-up (day 52) for medical history (baseline only), lung function, and clinical signs and symptoms of AECB (dyspnoea, cough, chest pain, expectoration, stethoscopic auscultation, body temperature and sputum colour and/or consistency). Venous blood samples were obtained at baseline and at the end of treatment. 103
4 Sputum samples were obtained at baseline, at the end of treatment and at follow-up. Patient compliance with medication was monitored at the end of treatment by counting tablets and recording patient information on tablet intake. Patients with < 80% compliance were excluded from the assessment of clinical efficacy, but were included in safety and tolerability evaluations. ASSESSMENT OF CLINICAL EFFICACY Clinical efficacy at the end of treatment and at follow-up was classified as cure (resolution of signs and symptoms to levels that existed before the exacerbation), improvement (resolution of fever but incomplete resolution of the other signs and symptoms of the exacerbation), failure (lack of resolution of any signs or symptoms or a need for additional antibiotic therapy), relapse (follow-up only; failure in a patient classified as cure or improvement at the end of treatment) or unevaluable. Lung function was evaluated by measuring the peak expiratory flow rate (PEFR; best of three measurements) using the Wright Peak Flow Meter (Clement Clarke, UK). Dyspnoea, cough, chest pain and expectoration were each assessed using a four-point scale (0 = not present, 1 = mild, 2 = moderate and 3 = severe). Sputum colour and/or consistency was graded as clear, white, purulent or brownish/reddish. Each patient was asked to complete two diaries (one for the treatment period and one for the follow-up period), and was trained in the use of the Wright Peak Flow Meter. Patients were asked to record their PEFR (twice daily during treatment, once weekly during followup; best result of three measurements), body temperature (once daily), expectoration (once daily, assessed as normal, improved, unchanged or worse) and well-being (once daily, assessed as normal, improved, unchanged or worse). Patient well-being was evaluated according to the time between baseline and the patient s first report of normal well-being (10 days, if no report of normal wellbeing was recorded at the end of treatment). ASSESSMENT OF BACTERIOLOGICAL EFFICACY Sputum samples were examined microscopically for the presence of bacteria, columnar cells and leucocytes, and by culture (2 days, 35 C) using 5% blood agar plates. Bacteriological efficacy at the end of treatment was classified as: eradication (absence of baseline pathogen); presumptive eradication (absence of adequate culturable material from a patient exhibiting clinical cure or improvement); improvement (eradication of some but not all baseline pathogens); persistence (presence of baseline pathogen); colonization (presence of pathogen not identified at baseline); superinfection (presence of pathogen not identified at baseline, associated with emergence or worsening of infection requiring antibiotic therapy); or unevaluable. No serology tests were performed. SAFETY ASSESSMENT Details of all adverse events, treatment discontinuations and clinical laboratory test results were recorded for patients receiving at least one dose of study drug. Venous blood samples were assayed for alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine, haemoglobin and leucocytes. STATISTICAL ANALYSIS Baseline, efficacy and safety data were analysed for differences between treatment groups. All statistical analyses were performed on an intention-to-treat basis and with a significance level of 5%. Patients who did not attend assessment at the end of treatment were excluded from primary evaluation. For quantitative data that were apparently normally distributed, the null hypothesis of no difference between means was tested using 104
5 Student s t-test. For data that were not normally distributed, the null hypothesis that the two samples were derived from the same population was tested using the Mann Whitney U-test. Treatment effect on PEFR was assessed by analysis of variance for repeated measures with unstructured covariances. 6 A null hypothesis for no difference between treatments was tested using the χ 2 test with a row-effects model. For qualitative data with two levels of outcome, a standard χ 2 test in 2 2 tables was used to test the null hypothesis that outcome was independent of treatment. Response categories were analysed by combining categories to generate 2 2 tables (clinical efficacy at end of treatment: cure versus improvement + failure; clinical efficacy at follow-up: cure versus improvement + relapse + failure; bacteriological efficacy at end of treatment: eradication or eradication + presumed eradication versus improvement + persistence + colonization). If one or more of the expected cell counts was less than five, Fisher s exact test was used. For outcomes with c (> 2) ordered levels, a log-likelihood test for independence, given that a row-effects model holds, was applied. 28 Patient well-being data were analysed using the log-rank test for survival data. RESULTS BASELINE CHARACTERISTICS Of 239 patients enrolled, 236 were randomized to treatment. Baseline characteristics and prognostic factors were generally similar in the two treatment groups (Table 1). A high proportion of patients in each treatment group had increased dyspnoea and increased coughing and expectoration; fewer patients in each group had an elevation in body temperature. The randomization of patients was skewed, however, due to intercentre variations in patient enrolment (azithromycin, 138; pivampicillin, 98; P = 0.011). In addition, the proportion of patients who were atopic was statistically TABLE 1 Characteristics and prognostic factors at baseline assessment in patients with acute exacerbations of chronic bronchitis Azithromycin a Pivampicillin b (n = 138) (n = 98) Mean age (range, years) 59.4 (26 87) 61.0 (20 85) Male (%) Weight (kg) Increase in dyspnoea (%) Increase in coughing and expectoration (%) Body temperature > 38.5 C (%) Peak expiratory flow rate (l/min) a 500 mg once daily. b 700 mg twice daily. 105
6 significantly lower for the azithromycin group than for the pivampicillin group (1.5% versus 12.1%; P < 0.001). CLINICAL EFFICACY The clinical success (cure or improvement) rate for azithromycin-treated patients (124 of 133, 93%) did not differ from that for pivampicillintreated patients (79 of 92, 86%) at the end of treatment (P > 0.05; Table 2). The clinical efficacy outcome for atopic patients was no different from that for non-atopic patients (data not shown). At follow-up, there was no statistically significant difference in clinical success rate between treatment groups (azithromycin, 98 of 126, 78%; pivampicillin, 66 of 81, 81%; P > 0.5; Table 2). The frequency of clinical relapse at follow-up was comparable for the two treatment groups (azithromycin, 22 of 126, 17%; pivampicillin, 11 of 81, 14%; P > 0.5). BACTERIOLOGICAL EFFICACY At the end of treatment, no statistically significant differences between treatment groups were observed with regard to bacteriological efficacy (eradication versus improvement + persistence + colonization, P > 0.05; eradication + presumed eradication versus improvement + persistence + colonization, P > 0.05; Table 3). Very few patients were able to produce a sputum specimen at follow-up; therefore, no analysis for this timepoint was performed. CLINICAL SIGNS AND SYMPTOMS For dyspnoea, cough, expectoration, sputum colour, sputum consistency and body temperature, no statistically significant differences between groups in the change in severity from baseline were observed, either at the end of treatment or at the end of the study (P > 0.05). The reduction in severity of chest discomfort was statistically significantly greater for azithromycin than for pivampicillin at the end of treatment (P = ); the two groups were comparable at follow-up (P = 0.22). Diary-card analysis showed that there was no significant difference in subjective improvement in patient TABLE 2 Clinical efficacy at end of treatment and at follow-up 42 days later (evaluable patients) in patients with acute exacerbations of chronic bronchitis treated with azithromycin (500 mg once daily) or pivampicillin (700 mg twice daily) No. (%) of patients End of treatment Follow-up Azithromycin Pivampicillin Azithromycin Pivampicillin (n = 133) (n = 92) (n = 126) (n = 81) Cure 40 (30%) 32 (35%) 63 (50%) 42 (52%) Improvement 84 (63%) 47 (51%) 35 (28%) 24 (30%) Success (cure + improvement) 124 (93%) 79 (86%) 98 (78%) 66 (81%) Relapse NA NA 22 (17%) 11 (14%) Failure 9 (7%) 13 (14%) 6 (5%) 4 (5%) NA, not applicable. 106
7 TABLE 3 Bacteriological efficacy at end of treatment (day 10; evaluable patients) in patients with acute exacerbations of chronic bronchitis treated with azithromycin (500 mg once daily) or pivampicillin (700 mg twice daily) No. (%) of patients Azithromycin Pivampicillin (n = 54) (n = 37) Eradication 36 (67%) 26 (70%) Presumed eradication 13 (24%) 6 (16%) Eradication + presumed eradication 49 (91%) 32 (86%) Improvement 0 1 (3%) Persistence 3 (6%) 3 (8%) Colonization 1 (2%) 1 (3%) Superinfection 1 (2%) 0 well-being (time to normalization) between the two treatments (P = 0.95). A trend (P = 0.052) towards a higher PEFR for azithromycin-treated patients compared with pivampicillin-treated patients was observed throughout the study; no significant differences in response were noted between treatment groups. SAFETY AND TOLERABILITY A total of 15 azithromycin- and 19 pivampicillin-treated patients withdrew from the study. Reasons for withdrawal included: adverse events (azithromycin, four patients; pivampicillin, five patients); conflicting concomitant medication (two and three patients, respectively); poor compliance (one patient in each group); loss to follow-up (two and four patients, respectively); and clinical failure (three patients in each group). There was no significant difference in withdrawal rates between the two treatment groups. The incidences of adverse events and treatment discontinuations were comparable for the two treatment groups. Of 138 patients randomized to treatment with azithromycin, 54 (39%) experienced at least one adverse event of any causality and 20 (14%) experienced at least one treatment-related adverse event. The corresponding values for pivampicillin-treated patients (n = 98) were 46 (47%) and 22 (22%). The most frequently reported treatment-related adverse events were diarrhoea (5%) and abdominal pain (5%) in the azithromycin group, and diarrhoea (11%) and nausea (3%) in the pivampicillin group. The rates of treatment discontinuation due to treatment-related adverse events were three of 138 (2%) for azithromycin and five of 98 (5%) for pivampicillin; the difference between treatment groups was not statistically significant. The treatment-related adverse events leading to withdrawal were rash, vomiting and diarrhoea for the azithromycin group, and diarrhoea, nausea, vomiting, stomatitis, weakness, gastritis and urticaria for the pivamipicillin group. 107
8 DISCUSSION β-lactam antibiotics have been used extensively to treat AECB. Their usefulness as empirical therapy is limited by increased β-lactamase production among causative pathogens, and by poor activity against the atypical respiratory pathogens. 29 In Denmark, there is a low incidence (< 1%) of penicillin resistance among S. pneumoniae strains. 30 The emergence of multiple daily dosing as a risk factor for patient non-compliance with medication 17,31 has increased the interest in finding simplified courses of antibiotic therapy that allow patient compliance to be optimized. Pivampicillin has a pharmacokinetic profile superior to that of ampicillin, and has demonstrated good clinical and bacteriological efficacy in the treatment of AECB. It must, however, be administered two or three times daily In contrast, azithromycin is notable for its good clinical efficacy achievable with a simple dosing regimen, comprising once-daily dosing for only 3 days. A study to provide a direct comparison between pivampicillin and azithromycin treatment regimens was therefore considered both useful and appropriate. The study was designed to have two treatment arms with equal numbers of patients. In fact, randomization was skewed such that more patients were treated with azithromycin. This reflected inter-centre variations in the numbers of patients enrolled and the distribution of patients between treatments in these centres, but it did not prevent statistical analysis of the difference in efficacy and/or safety between the two treatments. The two treatments were comparable with respect to clinical efficacy at the end of treatment and at follow-up. The clinical success rate for azithromycin at the end of treatment, which was in excess of 90%, is consistent with that observed across a number of published, comparator-controlled studies of azithromycin in the treatment of approximately 1000 patients with AECB (Pfizer Inc., data on file). The success rate for pivampicillin at end of treatment in the present study is lower than that reported previously among patients receiving pivampicillin 700 mg administered three times daily. 14 The present study used a dosing regimen of pivampicillin 700 mg administered twice daily, as recommended by the manufacturer. This study is noteworthy for its long follow-up period of 42 days after treatment. The clinical success rates recorded for both drugs at follow-up are impressive, given the considerable opportunity for relapse between the end-of-treatment and follow-up assessments. Azithromycin and pivampicillin also exhibited comparable bacteriological efficacy at the end of treatment. The pathogen eradication rate for azithromycin compares favourably with that observed in previously reported studies (79%; Pfizer Inc., data on file). The eradication rate for pivampicillin is lower than that reported 14 for patients receiving pivampicillin three times daily. In the present study, lung function and the clinical signs and symptoms of AECB tended to improve more rapidly for patients receiving azithromycin. This trend reached statistical significance for chest pain at end of treatment but not at follow-up. The subjective assessment of patient well-being using patient diary cards was an unusual feature of the study protocol, and provided a measure of the rate of improvement in clinical symptoms with time. In this study, its use was limited to the treatment period but extensions of the assessment to the full study period would be worth considering for future studies. Both treatment groups exhibited a high incidence of adverse events due to all causes, as expected for a study involving a long follow-up period. The adverse-event profile of azithromycin reported in this study is in agreement with the safety database drawn 108
9 from clinical trials with azithromycin. 26 Overall, the results of this study indicate that oral azithromycin is equivalent to oral pivampicillin in terms of clinical and bacteriological efficacy, as well as safety, and is an effective treatment for AECB. The simple, short-duration dosing regimen of azithromycin may, however, offer the opportunity to optimize patient compliance. ACKNOWLEDGEMENT This study was supported by a grant from Pfizer A/S, Denmark. REFERENCES 1 World Health Organization: The World Health Report 1999 Making a Difference. Geneva: World Health Organization, Niederman MS: Acute exacerbations of chronic bronchitis: the role of infection and the selection of appropriate therapy. Pulm Crit Care Update 1996; 11: Ball P, Harris J, Lowson D, et al: Acute infective exacerbations of chronic bronchitis. QJM 1995; 88: Chodosh S: Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med 1991; 91: 87S 92S. 5 Fagon J, Chastre J, Trouillet J, et al: Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: Ball P: Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S 52S. 7 Reynolds HY: Chronic bronchitis and acute infectious exacerbations. In: X. Principles and Practice of Infectious Diseases, 4th edn (Mandell GL, Bennett JE, Dollin R, eds). New York: Churchill Livingstone, 1995; pp File TM, Jr, Tan JS: Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med 1997; 3: Feldman C: Severe community-acquired pneumonia. Curr Opin Pulm Med 1997; 3: Saint S, Bent S, Vittinghoff E, et al: Antibiotics in chronic obstructive pulmonary disease exacerbations: a metaanalysis. JAMA 1995; 273: Anthonisen N, Manfreda J, Warren C, et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: Maesen F, Davies B: A clinical comparison of ampicillin, ampicillin esters (bacampicillin and pivampicillin) and amoxycillin in acute exacerbations of chronic bronchitis. Infection 1979; 7: S483 S Neu H: Aminopenicillins clinical pharmacology and use in disease states. Int J Clin Pharmacol Biopharm 1975; 11: Egede F, Kristensen I: A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1988; 22: Moran D: A multicentre general practice study comparing pivampicillin (Pondocillin) and amoxycillin (Amoxil) in respiratory tract infections. J Int Med Res 1983; 11: Admani A, Somasundrum U, Singh I: The management of elderly patients with acute lower respiratory tract infections: a comparison of pivampicillin and 109
10 amoxycillin. Curr Med Res Opin 1985; 9: Ballow CH: Cost considerations in oral antibiotic therapy. Adv Ther 1995; 12: Grob PR: Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis Suppl 1992; 83: Fiese EF, Steffen SH: Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25: Dunn C, Barradell L: Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51: Pontani D, Washton H, Bouchillon S, et al: Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998; 17: Gladue RP, Bright GM, Isaacson RE, et al: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: Gemmell C: Macrolides and host defences to respiratory tract pathogens. J Hosp Infect 1991; 19: Andrews JM, Honeybourne D, Brenwald NP, et al: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25: Hopkins SJ: Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994; 5: Medical Research Council s Committee on the Aetiology of Chronic Bronchitis: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; i: Diggle PJ, Liang K-Y, Zeger SL, et al: Analysis of Longitudinal Data. Oxford: Clarendon Press, Pechère JC, Gootz TD: Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis 1998; 17: Laursen SB, Konradsen HB: Group B streptococcal infections in adults. Ugeskr Laeger 1997; 159: Cockburn J, Gibberd RW, Reid AL, et al: Determinants of non-compliance with short-term antibiotic regimens. BMJ 1987; 295: P Schouenborg, N HH Rasmussen, N Wickers-Nielsen and E Mathiassen Azithromycin versus Pivampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis: a Single-blind, Double-dummy, Multicentre Study The Journal of International Medical Research 2000; 28: Received for publication 6 April 2000 Accepted 11 April 2000 Copyright 2000 Cambridge Medical Publications Address for correspondence DR P SCHOUENBORG Department of Microbiology, Vejle Hospital, Kabbeltoft 25, DK-7100, Vejle, Denmark. 110
JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationThe Importance of Appropriate Treatment of Chronic Bronchitis
...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,
More informationL. AUegra', N. Konietzko*, P. Leophonte% J. Hosie', R. Pauwels', J. N. Guyei/ and P. Petitpretz'
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. A, 93-104 Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind,
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationThe Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
...SYMPOSIUM PROCEEDINGS... The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Robert E. Hillberg, MD Presentation Summary Chronic obstructive pulmonary disease (COPD)
More informationDrug Class Review on Macrolides
Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationChronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
National Institute for Health and Care Excellence Final Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing Evidence review December 2018 Contents Disclaimer The recommendations
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 0./j.69-069.006.068.x Three vs. 0 days of amoxycillin clavulanic acid for type acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study B. M. Roede,
More informationan inflammation of the bronchial tubes
BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious
More informationL. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 125-131 A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Action Azithromycin
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman
More informationAntibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults
International Journal of Infectious Diseases (2005) 9, 274 279 http://intl.elsevierhealth.com/journals/ijid Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract
More informationEpidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell
LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
More informationHigh-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia
High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,
More information(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055
IJPSR (2014), Vol. 5, Issue 5 (Research Article) Received on 29 November, 2013; received in revised form, 21 February, 2014; accepted, 16 April, 2014; published 01 May, 2014 EVALUATION OF EFFICACY AND
More informationTherapeutic Challenges of Acute Bacterial Exacerbation of Chronic Bronchitis
...PRESENTATIONS... Therapeutic Challenges of Acute Bacterial Exacerbation of Chronic Bronchitis John Southard, MD, PhD Presentation Summary Determining the difference between colonization and infection
More informationComparison of First-Line With Second- Line Antibiotics for Acute Exacerbations of Chronic Bronchitis* A Metaanalysis of Randomized Controlled Trials
CHEST Comparison of First-Line With Second- Line Antibiotics for Acute Exacerbations of Chronic Bronchitis* A Metaanalysis of Randomized Controlled Trials Original Research George Dimopoulos, MD, FCCP;
More informationReceived 25 November 2002/Returned for modification 14 February 2003/Accepted 11 April 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2003, p. 2770 2774 Vol. 47, No. 9 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.9.2770 2774.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationCommunity Acquired Pneumonia. Abdullah Alharbi, MD, FCCP
Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules & Powder Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Azimex
More informationClinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection
Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection Sanford Chodosh Boston Veterans Administration Outpatient Clinic, Boston, Massachusetts, USA Studies in community-acquired
More informationKAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,
More informationCharles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history
More informationRespiratory tract infections. Krzysztof Buczkowski
Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria
More informationBronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
National Institute for Health and Care Excellence Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Disclaimer The
More informationComparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM)
Special Article Comparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM) Mukesh Aggarwal, Ramanuj Sinha 1, M. Vasudeva Murali 2, Prita
More informationFraser Health pandemic preparedness
Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE
More informationPneumonia. Dr. Rami M Adil Al-Hayali Assistant professor in medicine
Pneumonia Dr. Rami M Adil Al-Hayali Assistant professor in medicine Definition Pneumonia is an acute respiratory illness caused by an infection of the lung parenchyma, associated with recently developed
More informationQ-FEVER Q FEVER. CPMP/4048/01, rev. 3 1/7 EMEA 2002
Q FEVER CPMP/4048/01, rev. 3 1/7 General points on treatment Q fever is a zoonosis caused by Coxiella burnetii, an obligate intracellular gram-negative bacterium with high infectivity but with relatively
More informationCOPD Treatable. Preventable.
My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My
More informationCOPD exacerbation. Dr. med. Frank Rassouli
Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationAn open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 71-81 An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections B. O'Doherty
More informationCommunity-acquired pneumonia in adults
Prim Care Clin Office Pract 30 (2003) 155 171 Community-acquired pneumonia in adults Julio A. Ramirez, MD a,b, * a Department of Medicine, University of Louisville School of Medicine, 512 S. Hancock Street,
More informationCOPD guidelines in relation to infections: a critical analysis
All course materials, including the original lecture, are available as webcasts/podcasts at www.ers-educationorg pages/default. aspx?id=1339&idbrowse=47399 COPD guidelines in relation to infections: a
More informationTreatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
Eur Respir J, 1995, 8, 1999 2007 DOI: 10.1183/09031936.95.08121999 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Treatment of community-acquired
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationCefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1998, p. 729 733 Vol. 42, No. 4 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Cefepime versus Ceftriaxone for Empiric Treatment of
More informationManagement of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm
Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm DRUG PROFILE Gary Patou, Glenn Tillotson & Joseph Blondeau Author for correspondence University
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationAerobic gram-positive microorganisms Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes
AZIMEX Composition Each 5 ml contains Azithromycin (as dihydrate) 200 mg Powder Action Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfering with
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More informationPNEUMONIA IN CHILDREN. IAP UG Teaching slides
PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children
More informationUpper Respiratory Tract Infections
Upper Respiratory Tract Infections OTITIS MEDIA Otitis media is an inflammation of the middle ear. There are more than 709 million cases of otitis media worldwide each year; half of these cases occur in
More informationPhenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva
Journal of Antimicrobial Chemotherapy (1996) 7, 1-18 Phexymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva R. S.
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationNewer fluoroquinolones in the treatment of acute exacerbations of COPD
REVIEW Newer fluoroquinolones in the treatment of acute exacerbations of COPD Amit Patel Robert Wilson Royal Brompton Hospital, London UK Abstract: Acute exacerbations of COPD are a major cause of morbidity
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More informationMargaret A. Drehobl, MD; Maria C. De Salvo, MD; Drew E. Lewis, MD; and Jeanne D. Breen, MD
Single-Dose vs Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults* Margaret A. Drehobl, MD; Maria C. De Salvo, MD; Drew E. Lewis, MD; and Jeanne D. Breen, MD
More informationDiagnosis of Ventilator- Associated Pneumonia: Where are we now?
Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationWright, Respiratory Infections in the Challenging Patient. Disclosures. Objectives
Respiratory Infections in the Challenging Patient Wendy L. Wright, MS, APRN, BC, FAANP, FAAN Adult / Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst, New Hampshire Owner
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationWORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation
Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationManagement of Acute Exacerbations
15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationDose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7
AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo
More informationthe potentially harmful nature of these secretions3 s even when given in the apparently stable clinical state.
Thorax 1986;41:559-65 Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation SL HILL, HM MORRISON, D BURNETT, RA STOCKLEY
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationRespiratory Infections
Respiratory Infections NISHANT PRASAD, MD THE DR. JAMES J. RAHAL, JR. DIVISION OF INFECTIOUS DISEASES NEWYORK-PRESBYTERIAN QUEENS Disclosures Stockholder: Contrafect Corp., Bristol-Myers Squibb Co Research
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationPOLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
More informationSkin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease
Skin reactivity to autologous bacteria 149 Original Article Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease J. Halasa 1, M. Halasa
More informationUnit II Problem 2 Microbiology Lab: Pneumonia
Unit II Problem 2 Microbiology Lab: Pneumonia - What are the steps needed to obtain a proper sputum specimen? You need the following: A wide-mouth labeled container. Gloves. Water. Mouth wash + tissues.
More informationTRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 MERONEM 1 g, powder for solution for IV Injection Box of 10 vials (CIP: 387 830-6) Applicant: ASTRAZENECA
More informationCommunity Acquired Pneumonia
April 2014 References: 1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL Mace SE, McCracken Jr. GH, Moor MR, St. Peter SD, Stockwell JA, and Swanson JT. The Management of
More informationStudy on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward
HK J Paediatr (new series) 2002;7:33-38 Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward CM HUI, K TSE Abstract Objective: To estimate the incidence rate and risk factors
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRUFLOX Tablets (Prulifloxacin)
Published on: 10 Jul 2014 PRUFLOX Tablets (Prulifloxacin) Composition Each Film coated tablet contains: Prulifloxacin... 600 mg Colours: Red Oxide of Iron & Titanium Dioxide IP Dosage Form Tablet Pharmacology
More informationAciphin Ceftriaxone Sodium
Aciphin Ceftriaxone Sodium Only for the use of Medical Professionals Description Aciphin is a bactericidal, long-acting, broad spectrum, parenteral cephalosporin preparation, active against a wide range
More informationVANLID Capsules (Vancomycin hydrochloride)
Published on: 22 Sep 2014 VANLID Capsules (Vancomycin hydrochloride) Composition VANLID Capsules Each capsule contains: Vancomycin Hydrochloride IP equivalent to Vancomycin.. 250 mg Approved colours used
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationPfizer Laboratories (Pty) Ltd Zithromax One Approved Package Insert 26 June 2015 Page 1 of 14 APPROVED PACKAGE INSERT
Approved Package Insert 26 June 2015 Page 1 of 14 SCHEDULING STATUS S4 APPROVED PACKAGE INSERT PROPRIETARY NAME AND DOSAGE FORM (prolonged release granules for oral suspension) COMPOSITION Each bottle
More informationRESEARCH NOTE. 86 Clinical Microbiology and Infection, Volume 12 Number 1, January 2006
86 Clinical Microbiology and Infection, Volume 12 Number 1, January 2006 REFERENCES 1. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179 1181. 2. Barenfanger J, Drake
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationA comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever
Original article A comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever Dr Deo Bhushan, Dr Jadhav Jayashree, DR Nigavekar P V, DR Himanshu Kumar Department of Pediatrics,
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Azithromycin (Zedbac ) 500 mg powder for solution for infusion. Reference number: 2476 LIMITED SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Azithromycin (Zedbac ) 500 mg powder for solution for infusion Reference number: 2476 LIMITED SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationPULMONARY EMERGENCIES
EMERGENCIES I. Pneumonia A. Bacterial Pneumonia (most common cause of a focal infiltrate) 1. Epidemiology a. Accounts for up to 10% of hospital admissions in the U.S. b. Most pneumonias are the result
More informationRifaximin for Travellers Diarrhoea
New Medicines Profile April 2013 Issue No. 13.01 for Travellers Diarrhoea Concise evaluated information to support the managed entry of new medicines in the NHS Summary is a broad spectrum antibiotic licensed
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationNCT ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: HMR3647A_4019. Study Code: Telithromycin. Generic drug name:
Sponsor/company: Generic drug name: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription
More informationAnti-Microbial Drugs
Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,
More informationObjectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children
Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,
More informationClinical Comparative Study of Sulbactam/Ampicillin and Imipenem/Cilastatin in Elderly Patients with Community-Acquired Pneumonia
ORIGINAL ARTICLE Clinical Comparative Study of Sulbactam/Ampicillin and Imipenem/Cilastatin in Elderly Patients with Community-Acquired Pneumonia Katsunori Yanagihara 1,2, Yuichi Fukuda 1, Masafumi Seki
More information